A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.
Also called NCT05952869
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 303 participants
- Sponsor
- Registry
-
NCT05952869 -
2022-502782-14-00 -
U1111-1285-4257
-
- Other papers using this trial's data
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong SAR China, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05952869. Randomized; triple masking; primary purpose treatment. Start 2023-08-08 (actual); primary completion 2025-04-07 (actual). Results posted on 2026-02-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
- Condition
- Hypercholesterolemia
- Condition
- Familial Hypercholesterolemia
- Intervention (Drug)
- Enlicitide Decanoate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05952869- Content hash
e6275873d5a5c8f806b671b1d81e826b5f25dd39d8ab35b44864e2e617f6970c